G&E Herbal Biotechnology Co., Ltd. (TPEX: 4911)
Taiwan
· Delayed Price · Currency is TWD 55.40
+0.50 (0.91%)
Nov 20, 2024, 1:30 PM CST
G&E Herbal Biotechnology Cash Flow Statement
Financials in millions TWD. Fiscal year is January - December.
Millions TWD. Fiscal year is Jan - Dec.
Fiscal Year | TTM | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | 2018 - 2014 |
|---|---|---|---|---|---|---|---|
Period Ending | Jun '24 Jun 30, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 | Dec '20 Dec 31, 2020 | Dec '19 Dec 31, 2019 | 2018 - 2014 |
| Net Income | 83.82 | 72.4 | 7.38 | -19.88 | -14.3 | -23.37 | Upgrade
|
| Depreciation & Amortization | 9.55 | 9.33 | 9.4 | 9.33 | 9.21 | 9.22 | Upgrade
|
| Other Amortization | - | - | - | 0 | 0 | 0 | Upgrade
|
| Loss (Gain) From Sale of Assets | 0.33 | 0.01 | 0 | 0.02 | 0.01 | 0 | Upgrade
|
| Other Operating Activities | 20.82 | 17.98 | 0.71 | 1.67 | -2.51 | -4.15 | Upgrade
|
| Change in Accounts Receivable | -2.34 | -14.19 | 4.38 | 1.08 | -2.22 | -3.74 | Upgrade
|
| Change in Inventory | 3.8 | 1.74 | -5.69 | -2.85 | 0.14 | 3.13 | Upgrade
|
| Change in Accounts Payable | 0.93 | -2 | 2.47 | -0.35 | 0.35 | -0.03 | Upgrade
|
| Change in Unearned Revenue | 11.56 | 23.39 | 71.39 | 0.28 | 0 | 0.08 | Upgrade
|
| Change in Other Net Operating Assets | 4.68 | 4.82 | 9.92 | 1.52 | 10.09 | -0.56 | Upgrade
|
| Operating Cash Flow | 133.14 | 113.48 | 99.96 | -9.19 | 0.77 | -19.41 | Upgrade
|
| Operating Cash Flow Growth | 43.56% | 13.52% | - | - | - | - | Upgrade
|
| Capital Expenditures | -3.84 | -5.52 | -2.95 | -1.77 | -5 | -6.41 | Upgrade
|
| Sale (Purchase) of Intangibles | -0.07 | - | -0.01 | -0.22 | -1.77 | - | Upgrade
|
| Investment in Securities | -97.55 | -82.04 | 5.4 | 9 | 15.9 | 18.5 | Upgrade
|
| Other Investing Activities | -1.05 | -0.87 | 0.07 | - | -0.01 | 0.02 | Upgrade
|
| Investing Cash Flow | -102.5 | -88.43 | 2.51 | 7.01 | 9.13 | 12.11 | Upgrade
|
| Long-Term Debt Repaid | - | -0.12 | - | - | - | - | Upgrade
|
| Net Debt Issued (Repaid) | -0.46 | -0.12 | - | - | - | - | Upgrade
|
| Other Financing Activities | - | - | - | - | - | -0.79 | Upgrade
|
| Financing Cash Flow | -0.46 | -0.12 | - | - | - | -0.79 | Upgrade
|
| Net Cash Flow | 30.18 | 24.94 | 102.47 | -2.18 | 9.9 | -8.08 | Upgrade
|
| Free Cash Flow | 129.3 | 107.96 | 97.01 | -10.96 | -4.23 | -25.81 | Upgrade
|
| Free Cash Flow Growth | 48.99% | 11.29% | - | - | - | - | Upgrade
|
| Free Cash Flow Margin | 61.24% | 59.50% | 150.15% | -44.61% | -14.98% | -147.05% | Upgrade
|
| Free Cash Flow Per Share | 2.19 | 1.83 | 1.64 | -0.19 | -0.07 | -0.44 | Upgrade
|
| Cash Interest Paid | 0.02 | 0 | - | - | - | - | Upgrade
|
| Cash Income Tax Paid | 0.08 | 0.02 | - | - | - | - | Upgrade
|
| Levered Free Cash Flow | 113.95 | 67.88 | 93.19 | -5.52 | -7.17 | -21.93 | Upgrade
|
| Unlevered Free Cash Flow | 113.97 | 67.88 | 93.19 | -5.52 | -7.17 | -21.93 | Upgrade
|
| Change in Net Working Capital | -49.97 | -13.64 | -83.33 | 0.64 | -0.05 | 6.82 | Upgrade
|
Source: S&P Capital IQ. Standard template. Financial Sources.